Quetiapine XR
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Specific Phobia
Conditions
Specific Phobia
Trial Timeline
Apr 1, 2009 → Mar 1, 2011
NCT ID
NCT00872716About Quetiapine XR
Quetiapine XR is a phase 2 stage product being developed by AstraZeneca for Specific Phobia. The current trial status is completed. This product is registered under clinical trial identifier NCT00872716. Target conditions include Specific Phobia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00986167 | Approved | UNKNOWN |
| NCT01071135 | Phase 3 | Terminated |
| NCT00872716 | Phase 2 | Completed |
| NCT00681629 | Approved | Terminated |
| NCT00517387 | Phase 3 | Completed |
Competing Products
18 competing products in Specific Phobia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACR-2316 | Acrivon Therapeutics | Phase 1 | 25 |
| DJ-927 + capecitabine | Daiichi Sankyo | Phase 1 | 33 |
| E7389 + E7389 + E7389 | Eisai | Phase 1 | 33 |
| bevacizumab + enzastaurin hydrochloride | Eli Lilly | Phase 1 | 33 |
| Nasal Glucagon (NG) + Glucagon IM | Eli Lilly | Phase 3 | 77 |
| SHR-1916 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| PI3K inhibitor BKM120 + docetaxel | Novartis | Phase 1 | 33 |
| capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev) | Novartis | Phase 1 | 33 |
| warfarin | Novartis | Phase 1 | 33 |
| BEZ235 + MEK162 | Pfizer | Phase 1 | 32 |
| Ixabepilone + Sunitinib | Pfizer | Phase 1 | 32 |
| ixabepilone + lapatinib ditosylate | Bristol Myers Squibb | Phase 1 | 32 |
| carboplatin + irinotecan hydrochloride | Bristol Myers Squibb | Phase 1 | 32 |
| intoplicine | Sanofi | Phase 1 | 32 |
| apomine | Sanofi | Phase 1 | 32 |
| apomine | Sanofi | Phase 1 | 32 |
| Sorafenib | Bayer | Phase 2 | 49 |
| NKTR-214 | Nektar Therapeutics | Phase 1/2 | 36 |